{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:43:50Z","timestamp":1791607430950,"version":"4.3.4"},"reference-count":98,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Immunology"],"published-print":{"date-parts":[[2022,12,2]]},"DOI":"10.1080\/1744666x.2022.2128334","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T16:22:41Z","timestamp":1663863761000},"page":"1239-1251","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":13,"title":["Treatment strategies, including antibiotics, to target the immune component of rosacea"],"prefix":"10.1080","volume":"18","author":[{"given":"Kristen","family":"Delans","sequence":"first","affiliation":[{"name":"Wake Forest School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kelly","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine","place":["Winston-Salem, USA"]},{"name":"Wake Forest School of Medicine","place":["Winston-Salem, USA"]},{"name":"Wake Forest School of Medicine","place":["Winston-Salem, USA"]},{"name":"University of Southern Denmark","place":["Odense, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"crossref","DOI":"10.1080\/19381980.2017.1361574","article-title":"Rosacea: epidemiology, pathogenesis, and treatment","volume":"9","author":"Rainer BM","year":"2017","unstructured":"Rainer BM, Kang S, Chien AL. Rosacea: epidemiology, pathogenesis, and treatment. Dermatoendocrinol. 2017;9(1).","journal-title":"Dermatoendocrinol"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.049"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2016.6387"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00595-7"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.08.037"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.11.005"},{"key":"e_1_3_4_9_1","first-page":"S17","article-title":"Managing rosacea in the clinic: from pathophysiology to treatment-a review of the literature","volume":"13","author":"Johnson SM","year":"2020","unstructured":"Johnson SM, Berg A, Barr C. Managing rosacea in the clinic: from pathophysiology to treatment-a review of the literature. J Clin Aesthet Dermatol. 2020;13(4 Suppl 1):S17\u2013S22.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_4_10_1","first-page":"348","article-title":"Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life","volume":"6","author":"Huynh TT","year":"2013","unstructured":"Huynh TT. Burden of disease: the psychosocial impact of rosacea on a patient\u2019s quality of life. Am Health Drug Benefits. 2013;6(6):348\u2013354.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.043"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.53"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2230"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2017.11.002"},{"key":"e_1_3_4_15_1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-49274-2","volume-title":"Plewig and Kligman\u00b4s Acne and Rosacea","author":"Plewig G","year":"2019","unstructured":"Plewig G, Melnik B, Chen W. Acne Epidemiology and Genetics. Plewig and Kligman\u00b4s Acne and Rosacea. 4th ed. Springer Cham; 2019.","edition":"4"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00546-8"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14098"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14802"},{"key":"e_1_3_4_19_1","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13020","article-title":"Acne and rosacea: what\u2019s new for treatment?","volume":"32","author":"Dursun R","year":"2019","unstructured":"Dursun R, Daye M, Durmaz K. Acne and rosacea: what\u2019s new for treatment? Dermatol Ther. 2019;32(5):e13020.","journal-title":"Dermatol Ther"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00461-0"},{"issue":"11","key":"e_1_3_4_21_1","first-page":"803","article-title":"Topical treatments for rosacea","volume":"65","author":"Fritsch P","year":"2019","unstructured":"Fritsch P, Kolber MR, Korownyk C. Topical treatments for rosacea. Can Family Physician. 2019;65(11):803. College of Family Physicians of Canada.","journal-title":"Can Family Physician"},{"key":"e_1_3_4_22_1","first-page":"1457","article-title":"Rosacea: new and emerging treatments","volume":"74","author":"Moustafa FA","year":"2014","unstructured":"Moustafa FA, Sandoval LF, Feldman SR. Rosacea: new and emerging treatments. Drugs. Springer International Publishing. 2014;74(13):1457\u20131465.","journal-title":"Drugs. Springer International Publishing"},{"issue":"2","key":"e_1_3_4_23_1","first-page":"41","article-title":"An update on the treatment of rosacea","volume":"41","author":"Rivero AL","year":"2018","unstructured":"Rivero AL, Whitfeld M. An update on the treatment of rosacea. Aust Prescr. 2018;41(2):41.","journal-title":"Aust Prescr"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2021.1887138"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14816"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000446215"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10070757"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.043"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0339-0"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18857"},{"key":"e_1_3_4_31_1","first-page":"118","article-title":"A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines","volume":"74","author":"Del Rosso JQ","year":"2004","unstructured":"Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis. 2004;74(2):118\u2013122 .","journal-title":"Cutis"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s4296"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.140"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1159\/000235550"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.2165\/11530200-000000000-00000"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003226-200401000-00020"},{"key":"e_1_3_4_37_1","first-page":"22","article-title":"Immune signaling in rosacea","volume":"24","author":"Wladis EJ","year":"2021","unstructured":"Wladis EJ, Adam AP, Singhal D. Immune signaling in rosacea. Ocul Surf. 2021;24:22.","journal-title":"Ocul Surf"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17091562"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13143"},{"key":"e_1_3_4_41_1","unstructured":"Messoud A. Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea (STOP Ros) .ClinicalTrials.gov.2022 cited: 24 Sep 2022."},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.05.063"},{"key":"e_1_3_4_43_1","article-title":"Combined doxycycline 40 mg modified release capsules plus ivermectin 1% cream therapy for severe papulopustular rosacea","volume":"81","author":"Del Rosso J","year":"2019","unstructured":"Del Rosso J. Combined doxycycline 40 mg modified release capsules plus ivermectin 1% cream therapy for severe papulopustular rosacea. J Am Acad Dermatol. 2019;81(4).","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_44_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jdv.14437","article-title":"Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea","volume":"31","author":"Schaller M","year":"2017","unstructured":"Schaller M, Gonser L, Belge K, et al. Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea. J Eur Acad Dermatol Venereol. 2017;31 Suppl 4:31.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_4_45_1","doi-asserted-by":"crossref","first-page":"e14899","DOI":"10.1111\/dth.14899","article-title":"Rosacea with persistent facial erythema and high demodex density effectively treated with topical ivermectin alone or combined with oral carvedilol","volume":"34","author":"Huang HP","year":"2021","unstructured":"Huang HP, Hsu CK, Lee JYY. Rosacea with persistent facial erythema and high demodex density effectively treated with topical ivermectin alone or combined with oral carvedilol. Dermatol Ther. 2021;34(2):e14899.","journal-title":"Dermatol Ther"},{"key":"e_1_3_4_46_1","first-page":"1380","article-title":"Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials","volume":"13","author":"Gold LS","year":"2014","unstructured":"Gold LS, Kircik L, Fowler J, et al. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. Journal of Drugs in Dermatology .2014; 13(11):1380\u20131386.","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0133-6"},{"issue":"1","key":"e_1_3_4_48_1","first-page":"29","article-title":"Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea","volume":"29","author":"Sobolewska B","year":"2021","unstructured":"Sobolewska B, Doycheva D, Deuter CM, et al. Efficacy of topical ivermectin for the treatment of cutaneous and ocular rosacea. Ocul Immunol Inflamm. 2021;29(1):29.","journal-title":"Ocul Immunol Inflamm"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S98091"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1447562"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.05.003"},{"issue":"5","key":"e_1_3_4_52_1","first-page":"347","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong PY","year":"2002","unstructured":"Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(5):347.","journal-title":"N Engl J Med"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.06.057"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.04.022"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01624-x"},{"issue":"1","key":"e_1_3_4_56_1","first-page":"6","article-title":"Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication","volume":"7","author":"Parodi A","year":"2008","unstructured":"Parodi A, Paolino S, Greco A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol. 2008;7(1):6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.11.038"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12724"},{"key":"e_1_3_4_59_1","first-page":"67","article-title":"Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis","volume":"70","author":"Li Y","year":"2019","unstructured":"Li Y, Xie H, Deng Z, et al. Tranexamic acid ameliorates rosacea symptoms through regulating immune response and angiogenesis. Int Immunopharmacol. 2019;70:67.","journal-title":"Int Immunopharmacol"},{"key":"e_1_3_4_60_1","first-page":"607","article-title":"Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea","volume":"9","author":"Del Rosso JQ","year":"2010","unstructured":"Del Rosso JQ, Bruce S, Jarratt M, et al. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. Journal of Drugs in Dermatology. 2010;9(6):607\u201313.","journal-title":"Journal of Drugs in Dermatology"},{"issue":"1","key":"e_1_3_4_61_1","first-page":"56","article-title":"Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea","volume":"58","author":"Del Rosso JQ","year":"2007","unstructured":"Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;58(1):56.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_62_1","first-page":"7","article-title":"Systemic therapy for rosacea: focus on oral antibiotic therapy and safety","volume":"66","author":"Del Rosso JQ","year":"2000","unstructured":"Del Rosso JQ. Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis; cutaneous medicine for the practitioner. 2000;66(4 Suppl):7\u201313 .","journal-title":"Cutis; cutaneous medicine for the practitioner"},{"key":"e_1_3_4_63_1","first-page":"506","article-title":"The use of oral antibiotics in the management of rosacea","volume":"18","author":"Nagler AR","year":"2019","unstructured":"Nagler AR, and Del Rosso J. The use of oral antibiotics in the management of rosacea. J Drugs Dermatol. 2019;18(6):506.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_64_1","first-page":"5","article-title":"Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists","volume":"82","author":"Del Rosso JQ","year":"2008","unstructured":"Del Rosso JQ, Leyden JJ, Thiboutot D, et al. Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists. Cutis. 2008;82(2 Suppl 2):5\u201312.","journal-title":"Cutis"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.01.023"},{"key":"e_1_3_4_66_1","first-page":"44","article-title":"Open-label extension study evaluating the long-term safety, efficacy, and tolerability of FMX103 1.5% topical minocycline foam in the treatment of moderate-to-severe facial papulopustular rosacea","volume":"13","author":"Gold LS","year":"2020","unstructured":"Gold LS, Del Rosso J, Kircik L, et al. Open-label extension study evaluating the long-term safety, efficacy, and tolerability of FMX103 1.5% topical minocycline foam in the treatment of moderate-to-severe facial papulopustular rosacea. SKIN J Cutaneous Med. 2020;13(11):44\u201349.","journal-title":"SKIN J Cutaneous Med"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.5923"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.02.009"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03445.x"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00302"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.36849\/JDD.2020.5367"},{"key":"e_1_3_4_72_1","first-page":"641","article-title":"Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea","volume":"6","author":"Fowler JF","year":"2007","unstructured":"Fowler JF. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641\u20135.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0380-z"},{"issue":"2","key":"e_1_3_4_74_1","first-page":"53","article-title":"A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea","volume":"52","author":"Sanchez J","year":"2005","unstructured":"Sanchez J, Somolinos AL, Almod\u00f3var PI, et al. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;52(2 Suppl 1):53.","journal-title":"J Am Acad Dermatol"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.06.071"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9010185"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2017.07.005"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.10.062"},{"issue":"1","key":"e_1_3_4_79_1","first-page":"47","article-title":"Relationship between rosacea and sleep","volume":"47","author":"Wang Z","year":"2020","unstructured":"Wang Z, Xie H, Gong Y, et al. Relationship between rosacea and sleep. J Dermatol. 2020;47(1):47.","journal-title":"J Dermatol"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00460-1"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.14020"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.08.436"},{"key":"e_1_3_4_83_1","first-page":"5","article-title":"Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea","volume":"22","author":"Wirth PJ","year":"2017","unstructured":"Wirth PJ, Henderson Berg MH, Real-World SN. Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea. Skin Therapy Lett. 2017;22(6):5\u20137.","journal-title":"Skin Therapy Lett"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1616"},{"key":"e_1_3_4_85_1","first-page":"37","article-title":"The rosacea patient journey: a novel approach to conceptualizing patient experiences","volume":"95","author":"Kuo S","year":"2015","unstructured":"Kuo S, Huang KE, Davis SA, et al. The rosacea patient journey: a novel approach to conceptualizing patient experiences. Cutis. 2015;95(1):37\u201343.","journal-title":"Cutis"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.15.2699"},{"key":"e_1_3_4_87_1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-4632.2005.02769.x","article-title":"Azelaic acid (15% gel) in the treatment of acne rosacea","volume":"46","author":"Gupta AK","year":"2007","unstructured":"Gupta AK, Gover MD. Azelaic acid (15% gel) in the treatment of acne rosacea. Int J Dermatol. 2007;46 Suppl 2:46.","journal-title":"Int J Dermatol"},{"key":"e_1_3_4_88_1","first-page":"54","article-title":"A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea","volume":"96","author":"Draelos ZD","year":"2015","unstructured":"Draelos ZD, Elewski BE, Harper JC, et al. A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea. Cutis. 2015;96(1):54\u201361.","journal-title":"Cutis"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001030-00007"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/JDN.0000000000000237"},{"key":"e_1_3_4_91_1","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/archderm.139.11.1444","article-title":"Comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial","volume":"139","author":"Elewski BE","year":"2003","unstructured":"Elewski BE, Fleischer AB, Pariser DMA. Comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139(11):1444\u201350.","journal-title":"Arch Dermatol"},{"key":"e_1_3_4_92_1","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Gold LS","year":"2014","unstructured":"Gold LS, Kircik L, Fowler J, et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. Journal of Drugs in Dermatology. 2014;13(3):316\u201323.","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_3_4_93_1","unstructured":"Ble A. Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind Placebo-controlled Randomized Clinical Trial . Clinicaltrials.gov. 2019."},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15155"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630802314662"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.15210"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2012.711756"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2021.1922571"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.04.037"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02850197"}],"container-title":["Expert Review of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1744666X.2022.2128334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:39:17Z","timestamp":1770413957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/1744666X.2022.2128334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":98,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"alternative-id":["10.1080\/1744666X.2022.2128334"],"URL":"https:\/\/doi.org\/10.1080\/1744666x.2022.2128334","relation":{},"ISSN":["1744-666X","1744-8409"],"issn-type":[{"value":"1744-666X","type":"print"},{"value":"1744-8409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}